Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.
Yamashita N, Morimoto Y, Fushimi A, Ahmad R, Bhattacharya A, Daimon T, Haratake N, Inoue Y, Ishikawa S, Yamamoto M, Hata T, Akiyoshi S, Hu Q, Liu T, Withers H, Liu S, Shapiro GI, Yoshizumi T, Long MD, Kufe D. Yamashita N, et al. Among authors: withers h. Mol Cancer Res. 2023 Mar 1;21(3):274-289. doi: 10.1158/1541-7786.MCR-22-0772. Mol Cancer Res. 2023. PMID: 36445328 Free PMC article.
Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer.
Fushimi A, Morimoto Y, Ishikawa S, Yamashita N, Bhattacharya A, Daimon T, Rajabi H, Jin C, Hagiwara M, Yasumizu Y, Luan Z, Suo W, Wong KK, Withers H, Liu S, Long MD, Kufe D. Fushimi A, et al. Among authors: withers h. Mol Cancer Res. 2022 Sep 2;20(9):1379-1390. doi: 10.1158/1541-7786.MCR-22-0165. Mol Cancer Res. 2022. PMID: 35612556 Free PMC article.
NK Receptors Replace CD28 As the Dominant Source of Signal 2 for Cognate Recognition of Cancer Cells by TAA-specific Effector CD8+ T Cells.
Dong B, Obermajer N, Tsuji T, Matsuzaki J, Bonura C, Withers H, Long M, Chavel C, Olejniczak SH, Minderman H, Edwards RP, Storkus WJ, Romero P, Kalinski P. Dong B, et al. Among authors: withers h. Res Sq [Preprint]. 2023 Oct 19:rs.3.rs-3399211. doi: 10.21203/rs.3.rs-3399211/v1. Res Sq. 2023. PMID: 37886562 Free PMC article. Preprint.
MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells.
Yamashita N, Withers H, Morimoto Y, Bhattacharya A, Haratake N, Daimon T, Fushimi A, Nakashoji A, Thorner AR, Isenhart E, Rosario S, Long MD, Kufe D. Yamashita N, et al. Among authors: withers h. iScience. 2023 Oct 11;26(11):108168. doi: 10.1016/j.isci.2023.108168. eCollection 2023 Nov 17. iScience. 2023. PMID: 37915591 Free PMC article.
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs.
Dong B, Obermajer N, Tsuji T, Matsuzaki J, Bonura CM, Sander C, Withers H, Long MD, Chavel C, Olejniczak SH, Minderman H, Kirkwood JM, Edwards RP, Storkus WJ, Romero P, Kalinski P. Dong B, et al. Among authors: withers h. Cancer Immunol Res. 2024 Oct 1;12(10):1421-1437. doi: 10.1158/2326-6066.CIR-24-0061. Cancer Immunol Res. 2024. PMID: 38949179
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, Mechtler LL, Peereboom DM, Hutson AD, Withers HG, Liu S, Belal AN, Qiu J, Mogensen KM, Dharma SS, Dhawan A, Birkemeier MT, Casucci DM, Ciesielski MJ, Fenstermaker RA. Ahluwalia MS, et al. Among authors: withers hg. J Clin Oncol. 2023 Mar 1;41(7):1453-1465. doi: 10.1200/JCO.22.00996. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521103 Free PMC article. Clinical Trial.
281 results